Patents Assigned to Newave Pharmaceutical Inc.
  • BTK DEGRADER
    Publication number: 20240058457
    Abstract: The disclosure includes compounds of any one of Formulae (0)-(5), (A)-(E), (1)-(V), (11)-(20), as described herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 22, 2024
    Applicant: Newave Pharmaceutical Inc.
    Inventor: Yi Chen
  • BCL-2 inhibitors
    Patent number: 11903950
    Abstract: The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 20, 2024
    Assignee: Newave Pharmaceutical Inc.
    Inventor: Yi Chen
  • Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
    Patent number: 11680072
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: June 20, 2023
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Substituted pyrazines as inhibitors of BTK, and mutants thereof
    Patent number: 11501284
    Abstract: The disclosure includes compounds of Formula (I) wherein Q1, Q2, Q3, W, X, Y, Z1, m, n, Warhead, R1, R2, R3, R4, and R5, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 15, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventor: Yi Chen
  • Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
    Patent number: 11479555
    Abstract: The disclosure includes compounds of Formula (I) wherein Q, R1, R2, and m are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: October 25, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventor: Yi Chen
  • BCL-2 inhibitors
    Patent number: 11365206
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: June 21, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
    Patent number: 11279711
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: March 22, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Therapeutic agents for the treatment of HBV infection
    Patent number: 10501456
    Abstract: The disclosure includes compounds of Formula (I) wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: December 10, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Covalent inhibitors of CDK-7
    Patent number: 10456397
    Abstract: The disclosure includes compounds of Formula (I) wherein R0, R1, R2, R3, R4, R5, and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: October 29, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • BCL-2 inhibitors
    Patent number: 10377755
    Abstract: The disclosure includes compounds of Formula (I) wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: August 13, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Dual-warhead covalent inhibitors of FGFR-4
    Patent number: 10253029
    Abstract: The disclosure includes compounds of Formula (I) wherein Warhead1, Warhead2, R3, R4, R5, R6, R7, R8, Q, A, B, p, q, Z1, Z2, Z3, and Z4 are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 9, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Therapeutic agents for the treatment of HBV infection
    Patent number: 10239872
    Abstract: The disclosure includes compounds of Formula (I) wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 26, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Covalent inhibitors of CDK-7
    Patent number: 10195200
    Abstract: The disclosure includes compounds of Formula (I) wherein R0, R1, R2, R3, R4, R5, and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: February 5, 2019
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou